SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...
Johns Hopkins University said it would eliminate more than 2,000 jobs after the Trump administration rescinded funding for ...
Health and Me on MSN1d
Yearly Jab For HIV Protection Is Now Almost HereA yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
A new method is developed to track dormant HIV-infected cells. This breakthrough may lead to new treatments that eliminate ...
HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.
MASAKA, Uganda—Every morning for the past four years, Agnes Mutesi, 30, has taken a pill that prevents her from getting ...
To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback